Literature DB >> 9386146

Short-term anti-ischemic effect of 17beta-estradiol in postmenopausal women with coronary artery disease.

G M Rosano1, A M Caixeta, S Chierchia, S Arie, M Lopez-Hidalgo, W I Pereira, F Leonardo, C M Webb, F Pileggi, P Collins.   

Abstract

BACKGROUND: Short-term administration of 17beta-estradiol improves effort-induced myocardial ischemia in female patients with coronary artery disease. 17Beta-estradiol also has direct and indirect coronary vascular smooth muscle relaxing properties. The aim of the present study was to evaluate the effect of short-term administration of 17beta-estradiol on pacing-induced myocardial ischemia by means of continuous monitoring of coronary sinus pH in 16 postmenopausal female patients with coronary artery disease. METHODS AND
RESULTS: Patients underwent incremental atrial pacing starting at a rate of 100 bpm and increments of 20 bpm every 2 minutes up to 160 bpm before and 20 minutes after either 17beta-estradiol (1 mg sublingual, 9 patients) or placebo (sublingual, 7 patients). The time to the onset of myocardial ischemia during pacing was significantly increased by 17beta-estradiol (mean+/-SD, 254+/-36 versus 298+/-23 seconds; P<.02) but not by placebo (262+/-45 versus 256+/-34 seconds; P=NS) The pH shift was significantly reduced by 17beta-estradiol but not by placebo at every step of the pacing protocol. The maximum pH shift at peak pacing was significantly reduced by the administration of 17beta-estradiol by 0.022 pH units (95% CI, 0.001, 0.043; P<.04) but not by sublingual placebo (-0.002 pH units; 95% CI, -0.0073, 0.0021; P=NS). The maximum pH shift at maximum comparable pacing was also reduced by 17beta-estradiol by 0.015 pH units (95% CI, 0.012, 0.017; P<.001) but not by placebo (-0.0022 pH units; 95% CI, -0.006, 0.0015; P=NS).
CONCLUSIONS: 17Beta-estradiol reduces the degree of pacing-induced myocardial ischemia in postmenopausal patients with coronary artery disease. The reduction of pacing-induced coronary sinus pH shift is consistent with an anti-ischemic effect of the hormone and is not due to preconditioning, as evidenced by the absence of improvement after placebo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386146     DOI: 10.1161/01.cir.96.9.2837

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Nongenomic inhibition of coronary constriction by 17ß-estradiol, 2-hydroxyestradiol, and 2-methoxyestradiol.

Authors:  Brent J F Hill; Senetibeb Gebre; Bonnie Schlicker; Renée Jordan; Sean Necessary
Journal:  Can J Physiol Pharmacol       Date:  2010-02       Impact factor: 2.273

Review 2.  Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature.

Authors:  Susan E Bromley; Corinne S de Vries; Dawn Thomas; Richard D T Farmer
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting.

Authors:  Nancy A Nussmeier; Christina Mora-Mangano; Manuel Fontes; Nanette M Schwann; Dennis T Mangano
Journal:  Tex Heart Inst J       Date:  2005

4.  Effects of long-term hormone replacement therapy: results from a cohort study.

Authors:  S S Signorelli; S Sciacchitano; M Anzaldi; V Fiore; S Catanzaro; M Simili; S Neri
Journal:  J Endocrinol Invest       Date:  2010-04-22       Impact factor: 4.256

Review 5.  Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women.

Authors:  Richard E White; Ross Gerrity; Scott A Barman; Guichun Han
Journal:  Steroids       Date:  2010-01-07       Impact factor: 2.668

6.  Estrogen-induced improvement in coronary flow responses during atrial pacing in relation to endothelin-1 levels in postmenopausal women without coronary disease.

Authors:  Ioannis Kallikazaros; Costas Tsioufis; Panagiotis Zambaras; Ioannis Skiadas; Marina Toutouza; Dimitrios Tousoulis; Christodoulos Stefanadis; Pavlos Toutouzas
Journal:  Vasc Health Risk Manag       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.